FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 91 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 MOST POPULAR Our COVID-19 Response: How GreaterGood Is Making An Impact During The... April 23, 2020 Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma April 17, 2018 Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response April 4, 2018 What Happens If More People Get Screened for Cancer? January 26, 2024 Load more HOT NEWS Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... ¿Qué deben saber las personas con cáncer sobre el consumo de... Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... Patient Guide on Cancer Pain Management Now Available Also in French
